Research And Development Tenders

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Dronedarone (Atc Code According to Who: C01bd07)

Open House Procedure for Concluding Contracts for Special Interdisciplinary and Intersectoral Care for Patients with a Familial Increased Risk of Breast and Ovarian Cancer

Order Announcement - Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130 a Paragraph 8 Sgb V for Medicines with the Active Ingredient Rotigotine

Open House Originals Discount Agreements 2023-38 - Propranolol (Dosage Form: Oral Solution)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Maraviroc, Atc J05ax09 for the Period January 1St, 2024 - December 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Paliperidone (Exclusively 3-Month Depot), Atc N05ax13 for the Period January 1St, 2024 - December 31St, 2025

Medicines Called Botox(R) (Atc: M03ax21)

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Interferon Beta-1A (Rebif)

Framework agreement for maintenance of fire extinguishers and extinguishing water technology BBB-2023-0119

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V (Open House Model)